Atara Biotherapeutics, Inc.

ATRA Nasdaq CIK: 0001604464

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
Mailing Address 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
Phone 805-623-4211
Fiscal Year End 1231
EIN 460920988

Financial Overview

FY2025 FY

$128.94M
Revenue
$25.03M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report March 19, 2026 View on SEC
S-3 Shelf registration for future offerings March 17, 2026 View on SEC
10-K Annual financial report March 16, 2026 View on SEC
8-K Current report of material events March 16, 2026 View on SEC
424B5 Prospectus supplement March 16, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
4 Insider stock transaction report March 11, 2026 View on SEC
4 Insider stock transaction report March 11, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC
4 Insider stock transaction report March 4, 2026 View on SEC

Annual Reports

10-K March 16, 2026
  • Ebvallo™ (tab-cel) has secured European regulatory approval and is commercialized by Pierre Fabre.
  • A critical U.S. FDA approval decision for tab-cel is anticipated in late 2024 or early 2025.
View Analysis

Insider Trading

STRONG SELL 3 insiders 9 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.